Sign in

CIK 0001841387

  • Emerging growth company

Candel Therapeutics, Inc.

Sign in to watch
Ticker
CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
522214851
Phone
+1 617-916-5445
Business address
117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
  1. 4 Open-market buy Director bought 125,000 shares at $8.00 ($1,000,000)
  2. 4 Conversion Chief Scientific Officer acquired 162,137 shares (conversion)
  3. 4 Open-market buy Director bought 10,000 shares at $8.00 ($80,000)
  4. 4 Open-market buy Chief Executive Officer bought 25,000 shares at $8.00 ($200,000)
  5. 4 Conversion Director acquired 1,232,910 shares (conversion)
  6. 4 Open-market buy Chief Financial Officer bought 10,125 shares at $8.00 ($81,000)
  7. 4 Conversion Chief Medical Officer acquired 56,096 shares (conversion)
  8. 4 Open-market buy Chief Business Officer bought 6,000 shares at $8.00 ($48,000)
  9. 4 Open-market buy Director bought 56,000 shares at an average $7.34 ($410,778)
  10. 3 Insider Initial Statement of Ownership
  11. 3 Insider Initial Statement of Ownership
  12. 3 Insider Initial Statement of Ownership
  13. 3 Insider Initial Statement of Ownership
  14. 3 Insider Initial Statement of Ownership
  15. 3 Insider Initial Statement of Ownership
  16. 3 Insider Initial Statement of Ownership
  17. 3 Insider Initial Statement of Ownership
  18. 3 Insider Initial Statement of Ownership
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 10 of 11 · 202 filings